Back to mobile site

More on IVBIY

- Summary
- Chart
- Profile
- Historical

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

(OP:IVBIY)
Delayed: 40.30 --0 (-0%)
Prev. Close $40.30  
Open$40.30 
52 Wk High$ 
52 Wk Low$ 
Day High$40.30 
Day Low$40.30 
P/E N/A  
EPS$ 
Volume8,288 

Friends, Peers and Foes (?): 6IB, 83B, 3NX LLY (more...)

Jun 8, 2026 04:30 AM 2026 ADA | Innovent Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity & Metabolic Pipeline
Jun 4, 2026 04:35 AM Innovent submits gastric cancer drug for China regulatory review
Jun 4, 2026 04:35 AM World's First CLDN18.2 ADC for Regulatory Review: Innovent Biologics Announces IBI343 (arcotatug tavatecan) Met Primary Endpoint in International Phase 3 Study in Advanced Refractory Gastric Cancer an
May 31, 2026 08:00 PM 2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherap
May 31, 2026 08:00 PM 2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC
May 28, 2026 07:00 PM Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines
May 22, 2026 12:58 AM /C O R R E C T I O N -- Innovent Biologics/
May 21, 2026 07:50 PM 2026 ASCO Abstract Highlights | Innovent Announces Preliminary PoC data of IBI363 (PD-1/IL-2α-bias bispecific fusion protein) in Combination with Chemotherapy as First-line Treatment for Advanced NSC
May 21, 2026 07:49 PM 2026 ASCO Abstract Highlights: Innovent Biologics' IBI363 (PD-1/IL-2α-bias bispecific fusion protein) Demonstrates Robust Survival Benefits in Long-Term Follow-up of PoC Study in Advanced Immunothera
May 21, 2026 06:00 AM Innovent and HUTCHMED Jointly Announce NMPA Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Patients with Locally Advanced or Metastatic R
View All Articles

Entities mentioned with IVBIY

View All Entities